Dishman Carbogen Amcis Limited reported earnings results for the third quarter and nine months ended December 31, 2025. For the third quarter, the company reported sales was INR 7,198 million compared to INR 6,823.4 million a year ago. Revenue was INR 7,264.6 million compared to INR 6,879.7 million a year ago. Net loss was INR 129.7 million compared to net income of INR 46.3 million a year ago. Basic loss per share from continuing operations was INR 0.83 compared to basic earnings per share from continuing operations of INR 0.3 a year ago. Diluted loss per share from continuing operations was INR 0.83 compared to diluted earnings per share from continuing operations of INR 0.3 a year ago.
For the nine months, sales was INR 20,805 million compared to INR 19,951.6 million a year ago. Revenue was INR 21,200.2 million compared to INR 20,088.7 million a year ago. Net income was INR 757 million compared to net loss of INR 398.5 million a year ago. Basic earnings per share from continuing operations was INR 4.83 compared to basic loss per share from continuing operations of INR 2.54 a year ago. Diluted earnings per share from continuing operations was INR 4.83 compared to diluted loss per share from continuing operations of INR 2.54 a year ago.
Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS) and the manufacture and supply of marketable molecules such as specialty chemicals, vitamins and chemicals, and disinfectants. Its segments include CRAMS and Marketable Molecules. The CRAMS segment includes Contract Research Services and Contract Manufacturing Services, which it offers to its customers. Through its CRAMS business, the Company assists drug manufacturers in the development and optimization of processes for novel drug molecules in various stages of the development process. The Marketable Molecules segment manufactures and supplies intermediates, quaternary compounds, specialty chemicals, and various products for pharmaceuticals and cosmetics. It has manufacturing and research facilities in India, Switzerland, France, the Netherlands, the United Kingdom, and China. Its subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd., and others.
